Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**CSF-1R siRNA** is an experimental **small interfering RNA** therapeutic designed to silence **colony-stimulating factor 1 receptor** expression, typically in tumor-associated macrophages, in order to disrupt CSF-1/CSF-1R signaling and shift macrophages from an immunosuppressive M2-like state toward a more inflammatory M1-like phenotype. In the provided literature context, it is not a named commercial or clinical-stage drug product but rather a research-use RNA payload incorporated into an **M2pep-modified cyclodextrin nanoparticle** delivery system for prostate cancer immunotherapy. The reported therapeutic rationale is tumor microenvironment remodeling, increased cytotoxic T-cell recruitment, and antitumor activity in preclinical mouse models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CSF-1R siRNA.